Suven Pharmaceuticals Ltd - 543064 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on September 30, 2023 for Jasti Property and Equity Holdings Pvt Ltd & Venkateswarlu Jasti Suven Pharmaceuticals Ltd - 543064 - Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011.
The Exchange has received the Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011 on September 29, 2023 for Berhyanda Ltd & Berhyanda Midco Ltd Suven Pharmaceuticals Ltd - 543064 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on September 29, 2023 for Berhyanda Ltd & Berhyanda Midco Ltd Advent puts in place a new team to helm Suven Pharma
The company will be led by Annaswamy Vaidheesh as Executive Chairman, Dr V Prasada Raju as Managing Director, and Dr Sudhir Kumar Singh as Chief Executive Officer. Suven Pharmaceuticals Ltd - 543064 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Please find attached press release Suven Pharmaceuticals Ltd - 543064 - Announcement under Regulation 30 (LODR)-Change in Directorate
Outcome of the board meeting - Change in directors of the company Suven Pharmaceuticals Ltd - 543064 - Announcement under Regulation 30 (LODR)-Change in Management Control
Outcome of the board meeting - Intimation of change in control of the company and change in directors of the company Suven Pharmaceuticals Ltd - 543064 - Board Meeting Outcome for Outcome Of The Board Meeting - Intimation Of Change In Control Of The Company And Change In Directors Of The Company
This is in furtherance to the letter dated 26 December 2022 pursuant to which it was informed that, inter-alia a promoter of the Company i.e., Jasti Property and Equity Holdings Private Limited (in its capacity as sole trustee of Jasti Family Trust) ('Seller') has executed a share purchase agreement with Berhyanda Limited ('Acquirer'), a Cyprus based company on 26 December 2022 ('Share Purchase Agreement'). Suven Pharmaceuticals Ltd - 543064 - Intimation Under Regulation 30 Of SEBI (LODR) Regulations, 2015
We are pleased to inform you that the Company has received an intimation on September 25, 2023, that the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, has granted its approval for acquisition of upto 76.1% shareholding in the Company by M/s. Berhyanda Limited, Cyprus (Acquirer) by way of transfer of 12,75,37,043 equity shares aggregating to 50.1% of shareholding in the company from promoters of the Company and acquisition of up to 6,61,86,889 equity shares aggregating to 26% of shareholing in the Company from public shareholders through mandatory open offer. The aggregate foreign investment, including investment from other foreign investors may be up to 90.1% shareholding in the Company. Suven Pharmaceuticals Ltd - 543064 - Intimation Of Extension Of Time For Holding Annual General Meeting (AGM)
We wish to inform you that the Company, Suven Pharmaceuticals Limited filed an applicaiton before the Registrar of Companies, Hyderabad for an extension of holding Annual General Meeting (AGM) for the Financial Year 2022-23 which is due to be held on or before 30/09/2023 pursuant to the provisions of section 96(1) of the Companies Act, 2023. The Registrar of Companies, Hyderabad has approved the application and extended the date of AGM for 3 (three) months i.e. upto December 31, 2023.